Hyderabad: Dr Reddy’s Labs (DRL) on Wednesday said its subsidiary, Dr Reddy’s Labs SA, entered into commercialisation and licensing agreements with China’s Bio-Thera Solutions for biosimilars of two of Janssen’s human monoclonal antibodies (mABs) — Stelara (Ustekinumab) and Simponi (Golimumab) — for the Southeast Asian markets.
While Bio-Thera’s BAT2206 is a proposed biosimilar of Stelara, BAT2506 is a proposed biosimilar of Simponi that has been developed by Bio-Thera, a commercial-stage biopharmaceutical company that is developing a pipeline of innovative therapies and biosimilars.
As part of the agreement, Bio-Thera will develop, manufacture, and supply BAT2206 and BAT2506, while Dr Reddy’s will be responsible for seeking regulatory approvals and commercialising these two biosimilars in licensed territories in Southeast Asia, including Cambodia, Indonesia, Malaysia, Philippines, Thailand, and Vietnam.
Hyderabad-based Dr Reddy’s said it will also get exclusive commercial rights to market BAT2206 in Colombia as part of the deal.
Dr Reddy’s CEO for Branded Markets (India & Emerging Markets), MV Ramana said the partnership would enable the company to further expand its biosimilar offerings in emerging markets. “With our well-established commercial strengths in these markets, we look forward to addressing the unmet needs of patients with access to affordable medicines,” he said.
Bio-Thera CEO Dr Shengfeng Li said the partnership with Dr Reddy’s is the company’s first deal to be focused solely on Southeast Asia. “Dr Reddy’s is the perfect partner to help bring BAT2206 and BAT2506 to patients in the region. This collaboration with Dr Reddy’s demonstrates our commitment to the patients in Southeast Asia,” Li said.
